TB-500
Thymosin Beta-4 Fragment
Synthetic analogue of the naturally occurring Thymosin Beta-4 protein. Studied for promotion of angiogenesis, acceleration of wound-healing processes, and support of musculoskeletal recovery following acute injury.
Format
5mg / vial
Purity
>99.2%
Category
Recovery
Storage
2–8 °C
Research Price
€94
5mg / vial
RESEARCH USE ONLY
This compound is sold exclusively for in-vitro laboratory research. It is not intended for human consumption, therapeutic use, or self-administration. You must be 18+ and a qualified researcher to purchase.
Complete Your Research with the Pen Kit
Precise, painless, repeatable. The clinical-grade injection pen with 32G ultra-fine needles, bacteriostatic water, and your choice of peptide — ready to use out of the box.
€189
View details →Research Protocol Bundles
Recovery Stack
BPC-157 + TB-500 + GHK-Cu
The gold-standard soft-tissue repair protocol. Combines systemic repair (TB-500), localised healing (BPC-157), and skin/collagen regeneration (GHK-Cu) into a synergistic three-compound cycle.
Bundle total
€262
10% bundle saving
Documented Research Parameters
Research Dose
2–2.5 mg
Frequency
2× per week (loading), 1× per week (maintenance)
Duration
4–6 weeks loading, then as required
Half-Life
~4–6 hours (estimated)
Route(s)
Subcutaneous · Intramuscular
Solubility
Water
Reconstitution
2 ml bacteriostatic water per 5 mg vial
Key Research Findings
Actin-sequestering mechanism promotes cell migration — key to wound-healing cascade initiation.
Demonstrated cardioprotective effects via cardiomyocyte survival and angiogenesis.
Promotes neuronal plasticity in CNS injury models.
Anti-fibrotic properties studied in liver and cardiac tissue models.
Administration Reference
Subcutaneous injection in the abdominal region is the most documented route in research models. Rotating sites between left and right abdomen, outer thigh, and deltoid minimises local tissue response. Standard insulin syringes (29–31G) are appropriate. Loading phase protocols in the literature typically involve twice-weekly administration for the first 4–6 weeks.
Documented Combination Protocols
The canonical recovery stack — BPC-157 addresses cellular repair while TB-500 drives angiogenesis and actin remodelling.
IMPORTANT RESEARCH DISCLAIMER
This compound is for in-vitro research and laboratory use only. It has not been evaluated or approved by any regulatory authority for human therapeutic use. It must not be used as a food, drug, or cosmetic. SYNTHEXA assumes no liability for misuse. Handle in accordance with Good Laboratory Practice.